RxDoctor Payments Data

Harish Patlolla, MD

Cardiovascular Disease · Moline, ILNPI 1528323870

Payments from drug & device makers

$13,417in general payments, 2019–2025

Across 524 payments — averaging $25.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$1K
  • Novartis$1K
  • Medtronic$1K
  • Johnson & Johnson$936
  • Abiomed$930
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$865
  • plus $7K from 40 others

What the payments were for

  • Travel & lodging$1,48811%
  • Food & beverage$11,60286%
  • Education$2372%
  • Gifts$751%
  • Entertainment$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,417 in reported general payments places this provider in the 80th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$414,436
Medicare patients
1,394
Services billed
4,439

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis61$1,375,227
EliquisApixaban380$361,848
EntrestoSacubitril/Valsartan158$161,277
XareltoRivaroxaban140$140,539
JardianceEmpagliflozin110$94,251
FarxigaDapagliflozin Propanediol45$39,788
BrilintaTicagrelor34$33,705
Repatha SureclickEvolocumab26$33,359
MultaqDronedarone Hcl28$29,386
Praluent PenAlirocumab23$17,135
NexlizetBempedoic Acid/Ezetimibe19$16,034
VascepaIcosapent Ethyl17$12,360
Dabigatran EtexilateDabigatran Etexilate Mesylate35$6,418
Metoprolol Succinate451$5,597
Rosuvastatin Calcium505$4,671

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$455$1,737,075441 claims
NovartisEntresto$1,229$161,277158 claims
Johnson & JohnsonXarelto$936$140,539140 claims
Boehringer IngelheimJardiance, Pradaxa$748$98,407121 claims
AstraZenecaFarxiga, Brilinta$831$73,49479 claims
Sanofi-aventis U.S. LLCMultaq$86$29,38628 claims
Esperion Therapeutics, Inc.Nexlizet$532$16,03419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in Moline

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →